Xiaojing Wang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/565262/publications.pdf

Version: 2024-02-01

45 papers	2,182 citations	304743 22 h-index	233421 45 g-index
47 all docs	47 docs citations	47 times ranked	3259 citing authors

#	Article	IF	Citations
1	<scp>FUNDC</scp> 1 regulates mitochondrial dynamics at the <scp>ER</scp> â€“mitochondrial contact site under hypoxicÂconditions. EMBO Journal, 2016, 35, 1368-1384.	7.8	260
2	Circular RNA circAGO2 drives cancer progression through facilitating HuR-repressed functions of AGO2-miRNA complexes. Cell Death and Differentiation, 2019, 26, 1346-1364.	11.2	223
3	The LPS-inducible lncRNA Mirt2 is a negative regulator of inflammation. Nature Communications, 2017, 8, 2049.	12.8	218
4	Circ-HuR suppresses HuR expression and gastric cancer progression by inhibiting CNBP transactivation. Molecular Cancer, 2019, 18, 158.	19.2	157
5	Cis-Acting circ-CTNNB1 Promotes Î²-Catenin Signaling and Cancer Progression via DDX3-Mediated Transactivation of YY1. Cancer Research, 2019, 79, 557-571.	0.9	128
6	Increased Killing of Liver NK Cells by Fas/Fas Ligand and NKG2D/NKG2D Ligand Contributes to Hepatocyte Necrosis in Virus-Induced Liver Failure. Journal of Immunology, 2010, 184, 466-475.	0.8	121
7	Therapeutic targeting of circâ€•<scp>CUX</scp> 1 / <scp>EWSR</scp> 1/ <scp>MAZ</scp> axis inhibits glycolysis and neuroblastoma progression. EMBO Molecular Medicine, 2019, 11, e10835.	6.9	101
8	Long Noncoding RNA pancEts-1 Promotes Neuroblastoma Progression through hnRNPK-Mediated Î²-Catenin Stabilization. Cancer Research, 2018, 78, 1169-1183.	0.9	79
9	HPSE enhancer RNA promotes cancer progression through driving chromatin looping and regulating hnRNPU/p300/EGR1/HPSE axis. Oncogene, 2018, 37, 2728-2745.	5.9	76
10	Renalase is a novel target gene of hypoxia-inducible factor-1 in protection against cardiac ischaemiaâ€“reperfusion injury. Cardiovascular Research, 2015, 105, 182-191.	3.8	45
11	Potential contribution of increased soluble IL-2R to lymphopenia in COVID-19 patients. Cellular and Molecular Immunology, 2020, 17, 878-880.	10.5	45
12	Fibrinogen-like protein 2 aggravates nonalcoholic steatohepatitis via interaction with TLR4, eliciting inflammation in macrophages and inducing hepatic lipid metabolism disorder. Theranostics, 2020, 10, 9702-9720.	10.0	41
13	Armadillo repeat containing 12 promotes neuroblastoma progression through interaction with retinoblastoma binding protein 4. Nature Communications, 2018, 9, 2829.	12.8	37
14	Clinical characteristics and risk factors of liver injury in COVID-19: a retrospective cohort study from Wuhan, China. Hepatology International, 2020, 14, 723-732.	4.2	35
15	The mechanism underlying extrapulmonary complications of the coronavirus disease 2019 and its therapeutic implication. Signal Transduction and Targeted Therapy, 2022, 7, 57.	17.1	34
16	Ets-1 promoter-associated noncoding RNA regulates the NONO/ERG/Ets-1 axis to drive gastric cancer progression. Oncogene, 2018, 37, 4871-4886.	5.9	33
17	microRNA-558 facilitates the expression of hypoxia-inducible factor 2 alpha through binding to 5â€²-untranslated region in neuroblastoma. Oncotarget, 2016, 7, 40657-40673.	1.8	32
18	p113 isoform encoded by CUX1 circular RNA drives tumor progression via facilitating ZRF1/BRD4 transactivation. Molecular Cancer, 2021, 20, 123.	19.2	31

#	Article	IF	Citations
19	Immunological Characteristics in Type 2 Diabetes Mellitus Among COVID-19 Patients. Frontiers in Endocrinology, 2021, 12, 596518.	3.5	30
20	End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB. Journal of Hepatology, 2022, 77, 42-54.	3.7	28
21	Absence of Interferon Regulatory Factor 1 Protects Against Atherosclerosis in Apolipoprotein E-Deficient Mice. Theranostics, 2019, 9, 4688-4703.	10.0	26
22	Long Noncoding RNA NHEG1 Drives Î²-Catenin Transactivation and Neuroblastoma Progression through Interacting with DDX5. Molecular Therapy, 2020, 28, 946-962.	8.2	26
23	Therapeutic targeting of SPIB/SPI1â€facilitated interplay of cancer cells and neutrophils inhibits aerobic glycolysis and cancer progression. Clinical and Translational Medicine, 2021, 11, e588.	4.0	24
24	Therapeutic targeting of YY1/MZF1 axis by MZF1-uPEP inhibits aerobic glycolysis and neuroblastoma progression. Theranostics, 2020, 10, 1555-1571.	10.0	21
25	Immune mediated liver failure. EXCLI Journal, 2014, 13, 1131-44.	0.7	20
26	Liver TCRÎ³Î´+ CD3+ CD4â^' CD8â^' T cells contribute to murine hepatitis virus strain 3-induced hepatic injury through a TNF-Î±-dependent pathway. Molecular Immunology, 2012, 52, 229-236.	2.2	19
27	Definition of ACLF and inclusion criteria for extra-hepatic organ failure. Hepatology International, 2015, 9, 360-365.	4.2	19
28	Hepatitis B virus genotype B and mutations in basal core promoter and pre-core/core genes associated with acute-on-chronic liver failure: a multicenter cross-sectional study in China. Hepatology International, 2014, 8, 508-516.	4.2	18
29	Smad4 suppresses the tumorigenesis and aggressiveness of neuroblastoma through repressing the expression of heparanase. Scientific Reports, 2016, 6, 32628.	3.3	16
30	Targeting NFATc4 attenuates non-alcoholic steatohepatitis in mice. Journal of Hepatology, 2020, 73, 1333-1346.	3.7	16
31	Therapeutic targeting of the USP2-E2F4 axis inhibits autophagic machinery essential for zinc homeostasis in cancer progression. Autophagy, 2022, 18, 2615-2635.	9.1	16
32	Intracellular hepatitis B virus increases hepatic cholesterol deposition in alcoholic fatty liver via hepatitis B core protein. Journal of Lipid Research, 2018, 59, 58-68.	4.2	15
33	Epoxyeicosatrienoic acids alleviate methionineâ€cholineâ€deficient dietâ€“induced nonâ€alcoholic steatohepatitis in mice. Scandinavian Journal of Immunology, 2019, 90, e12791.	2.7	15
34	Ciliary Neurotrophic Factor-treated Astrocyte Conditioned Medium Regulates the L-type Calcium Channel Activity in Rat Cortical Neurons. Neurochemical Research, 2008, 33, 826-832.	3.3	13
35	CD4â€“CD8-T cells contribute to the persistence of viral hepatitis by striking a delicate balance in immune modulation. Cellular Immunology, 2012, 280, 76-84.	3.0	9
36	A disparate subset of double-negative T cells contributes to the outcome of murine fulminant viral hepatitis via effector molecule fibrinogen-like protein 2. Immunologic Research, 2016, 64, 518-530.	2.9	9

#	Article	IF	Citations
37	Nkx2â€5 Is Expressed in Atherosclerotic Plaques and Attenuates Development of Atherosclerosis in Apolipoprotein Eâ€"Deficient Mice. Journal of the American Heart Association, 2016, 5, .	3.7	8
38	HNF4A-AS1-encoded small peptide promotes self-renewal and aggressiveness of neuroblastoma stem cells via eEF1A1-repressed SMAD4 transactivation. Oncogene, 2022, 41, 2505-2519.	5.9	8
39	Noninvasive measurement of liver fibrosis by transient elastography and influencing factors in patients with chronic hepatitis Bâ€"A single center retrospective study of 466 patients. Journal of Huazhong University of Science and Technology [Medical Sciences], 2012, 32, 69-74.	1.0	7
40	Inhibitory function of Tregs via soluble FGL2 in chronic hepatitis B. Journal of Huazhong University of Science and Technology [Medical Sciences], 2012, 32, 540-545.	1.0	4
41	Comparison of transumbilical multiport and standard laparoscopic pyeloplasty in children: Mid-term results at a single center. Journal of Pediatric Surgery, 2017, 52, 473-477.	1.6	4
42	Hepatic exosomes with declined <scp>MiR</scp>â€27bâ€3p trigger <scp>RIGâ€I</scp>/<scp>TBK1</scp> signal pathway in macrophages. Liver International, 2022, 42, 1676-1691.	3.9	3
43	A Robust Prognostic Signature of Tumor Microenvironment in Colorectal Cancer. Cancer Biotherapy and Radiopharmaceuticals, 2022, 37, 963-975.	1.0	2
44	The Role of Metabolic Factors and Steatosis in Treatment-NaÃ¯ve Patients with Chronic HepatitisÂB and Normal Alanine Aminotransferase. Infectious Diseases and Therapy, 2022, 11, 1133-1148.	4.0	2
45	Highâ€fatâ€induced nonalcoholic fatty liver potentiates vulnerability to and the severity of viral hepatitis in a <scp>C3H</scp> / <scp>HeN</scp> mouse model. BioFactors, 2022, 48, 216-227.	5.4	0